ArticleFrontiers in immunology2026
Calcitonin gene-related peptide promotes mast cell-mediated neuroimmune inflammation through the CALCRL/RAMP1-JAK3-STAT1 axis in rosacea.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Rosacea is a chronic inflammatory skin disorder characterized by neurovascular instability and dysregulated innate immunity. Although mast-cell activation is increasingly recognized as a central pathogenic feature, the neuroimmune mechanisms linking neuropeptide signaling to mast cell-mediated inflammation remain incompletely defined. This study investigated whether calcitonin gene-related peptide (CGRP) promotes mast cell-mediated inflammation in rosacea and explored the underlying signaling mechanism. Methods: Bioinformatic analyses of the GSE65914 dataset were performed to characterize rosacea-associated molecular pathways and mast-cell signatures. Serum and skin samples from patients with rosacea and healthy controls were analyzed by ELISA, histological staining, and immunofluorescence. Results: Rosacea lesions showed enrichment of immune-inflammatory pathways, JAK-STAT signaling, and mast cell-associated signatures. Serum CGRP levels were elevated in patients with rosacea and positively correlated with flushing and erythema severity. Lesional skin showed increased CGRP expression and enhanced localization of CALCRL, RAMP1, phosphorylated JAK3, and phosphorylated STAT1 in dermal CD117+ mast cells. In LUVA mast cells, CGRP upregulated CALCRL/RAMP1 expression, activated JAK3-STAT1 signaling, and promoted degranulation, histamine release, and inflammatory mediator production. Molecular docking and reciprocal co-immunoprecipitation supported a potential association between CALCRL and JAK3. Rimegepant or ritlecitinib attenuated CGRP-induced JAK3-STAT1 activation and mast-cell responses. Modulation of the canonical Gαs-cAMP-PKA pathway did not abolish CGRP-induced JAK3-STAT1 phosphorylation, indicating that this response is not primarily mediated by the cAMP-PKA cascade. Conclusion: These findings identify a CGRP-associated neuroimmune pathway in rosacea in which CALCRL/RAMP1-linked JAK3-STAT1 signaling promotes mast cell-mediated inflammatory amplification. Targeting the CGRP-CALCRL/RAMP1-JAK3-STAT1 axis may provide a mechanism-based therapeutic strategy for neurovascular-dominant or treatment-refractory rosacea.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.